Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

descriptionPublicationkeyboard_double_arrow_right Article 15 Apr 2013 English Publisher:WileyJournal:Journal of Cutaneous Pathology, volume 40, pages 667-669 (issn: 0303-6987, eissn: 1600-0560,

Copyright policy )

Authors: Gene H, Kim; Alan, Levy; Goli, Compoginis;

doi: 10.1111/cup.12149

pmid: 23581649

Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

- Summary
- Subjects
- Metrics

Abstract

Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.

Related Organizations

University of Southern California
United States
University of California System
United States

Keywords

Proto-Oncogene Proteins B-raf, Sulfonamides, Indoles, Panniculitis, Mutation, Missense, Middle Aged, Amino Acid Substitution, Vemurafenib, Humans, Female, Neoplasm Metastasis, Melanoma

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	36
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%